Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CareDx ( (CDNA) ) just unveiled an announcement.
On April 15, 2026, CareDx agreed to sell its Swedish subsidiary CareDx AB and its global Lab Products business, which includes HLA typing and post-transplant monitoring IVD kits, to Eurobio Scientific for $170 million in cash, subject to customary adjustments and regulatory approvals. The deal includes transition services, exclusive North American distribution rights for certain Eurobio post-transplant assays to CareDx, and limited rights for Eurobio to continue serving existing chimerism assay customers.
CareDx said the divestiture, approved by both companies’ boards and expected to close by the end of its third quarter of 2026, is designed to sharpen focus on its higher-growth Precision Medicine Testing Services and Patient and Digital Solutions while simplifying its operating model and improving financial flexibility. The company reported strong preliminary first-quarter 2026 results, with total revenue up 39% year over year to about $118 million and testing services revenue up 48%, while the Lab Products segment declined 4%, underscoring the strategic rationale to redeploy capital into its faster-growing core business.
The most recent analyst rating on (CDNA) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.
Spark’s Take on CDNA Stock
According to Spark, TipRanks’ AI Analyst, CDNA is a Neutral.
The score is driven primarily by improving cash generation and a conservative balance sheet, plus supportive 2026 growth/margin/EBITDA guidance from the latest earnings call. Offsetting these positives are inconsistent GAAP profitability and weak near-term technical momentum, with limited valuation support due to a negative P/E and no dividend.
To see Spark’s full report on CDNA stock, click here.
More about CareDx
CareDx, Inc., listed on Nasdaq as CDNA, is a precision medicine company focused on improving outcomes for transplant patients and advancing organ health. Its integrated portfolio includes non-invasive molecular tests for heart, kidney and lung transplants, in vitro diagnostic kits, digital health technologies and patient support solutions, with a primary market focus on genomics-based information for transplant care.
Eurobio Scientific is a specialty in vitro diagnostics player active from research through commercialization of tests in transplantation, immunology and infectious diseases. It serves hospitals, research laboratories and biopharma clients with a proprietary product portfolio and an extensive distribution network that supports its diagnostics and reagent offerings.
Average Trading Volume: 630,245
Technical Sentiment Signal: Sell
Current Market Cap: $899.9M
See more insights into CDNA stock on TipRanks’ Stock Analysis page.